Management of T1 Kidney Cancer Laparoscopic Surgery

Slides:



Advertisements
Similar presentations
Regional Perspectives on Renal Cell Carcinoma Mohamed Abdulla M.D. Professor of Clinical Oncology Cairo University AfME. September 17 th 2010W:
Advertisements

CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago.
CLINICAL CHARACTERISTICS AND OUTCOMES FOR BENIGN AND MALIGNANT SOLITARY FIBROUS TUMOR / HEMANGIOPERICYTOMA (SFT/HPC) – A SINGLE CENTER EXPERIENCE Nicholas.
Interventional Oncology Michael Kotton MD October 27, 2012.
Long-Term Survival Following Hepatectomy for Hepatocellular Carcinoma Sheung Tat FAN Department of Surgery, The University of HongKong Chair Professor.
Renal Tumours n Mr C Dawson MS FRCS n Consultant Urologist n Fitzwilliam Hospital n Peterborough.
Renal Cell Carcinoma & Other Solid renal lesions Dr Charles Chabert POW May 2005.
59 years old man Hx of stomach adenocarcinoma 20 years ago Hx of chemoradiotherapy cc:gross hematuria.
High-Grade T1 Bladder Cancer: A Clinical Quandary Daniel Canter, M.D. Assistant Professor of Urology Emory University presentation created for:
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Radical Prostatectomy: A Critical Analysis of Surgical Quality Between the Open and Laparoscopic Approaches. Karim Touijer, MD.
WHICH NEPHRECTOMY. laparoscopic nephrectomy Simple laparoscopic nephrectomy. Donor laparoscopic nephrectomy. Radical laparoscopic nephrectomy. Partial.
Controversies in Surgical Management of Renal Cancer Maurizio Brausi Chairman Dept. of Urology Ausl Modena Chairman ESOU (European Section Onco-Urology)
Management of Small renal tumors
CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;
Management of Colorectal Liver Metastasis
IN THE NAME OF GOD.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.
Laparoscopic Pancreatectomy Attila Nakeeb, M.D., F.A.C.S. Department of Surgery Indiana University School of Medicine 7th Annual Symposium on Gastrointestinal.
Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.
Current Role of Partial Cystectomy: Are we scarifying patient ’ s survival Dr Eric Li Department of Surgery Pamela Youde Nethersole hospital.
Treatment Options for Renal Cell Carcinoma By: Anthony Jurayj.
Renal cell cancer: Integrating novel agents into a therapeutic algorithm Robert Dreicer, M.D., FACP Chairman Department of Solid Tumor Oncology Taussig.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Does the embolization of the tumor, prior to radical nephrectomy, prologs the life of patients with renal cell carcinoma * Department of Urology Regional.
Investigation of CA9 expression in pulmonary metastatic lesions from patients with clear cell renal cell carcinoma Pierre Tennstedt 1, Peter Schneider.
Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.
Thyroid Debate (Papillary Thyroid Cancer: Extent of Thyroidectomy) 30 Aug 2007 Surgery-OMMC JGGuerra, MD HCruz, MD.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Renal Cryoablation. 1. Morbidity 2. Efficacy Cancer Free Survival (NED) Cancer Free Survival (NED) Cancer Specific Survival Cancer Specific Survival Post.
UofT GU Oncology, 2004 CLINICAL CASES. UofT GU Oncology, y.o. female  Familiar history: Thyroid cancer (mother) Prostate cancer (father)  PMH:
“INTEGRAZIONE TRA TERAPIA CHIRURGICA E TERAPIA MEDICA” Camillo Porta, MD Medical Oncology I.R.C.C.S. San Matteo University Hospital Foundation, Pavia.
Data from The Johns Hopkins Renal Mass Registry
Visceral Adiposity at Diagnosis Correlates with Tumor Size and Metastatic Progression in Clear Cell Renal Carcinoma A Shuster, MD (1), M Patlas, MD (1),
Interesting case. OD yo man with irretrievable rectal TVA on screening colonoscopy, prior transanal excision 8 cm from anal verge Pmhx: hypothyroidism,
Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
Radical Nephrectomy The Role Of Surgery In mRCC Peter Mulders Professor and Chairman Department of Urology University Medical Center Nijmegen The Netherlands.
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
Radical vs Partial Nephrectomy for treatment of renal cell carcinoma at Prince Hussein Urology Centre Dr. Mohammad Alserhan Urology specialist Prince Hussein.
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Renal cell carcinoma R4 신재령 Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma.
Pt ZJ 19yo M that presented to Seattle Children’s for evaluation of 3 lesions found on recent PET CT ◦ One large mass in the posterior mediastinum just.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Alon Z. Weizer, MD, MS Associate Professor of Urology
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
Prevalence of Renal Tumors in Tertiary Care Hospital, Lahore, Pakistan Muhammad Nadeem, MBBS. Research Scholar, Applied for residency Dr. Nauman Ahmed,
Renal cell carcinoma : alternative treatment LUKMAN HAKIM DEPARTMENT OF UROLOGY, AIRLANGGA UNIVERSITY/DR. SOETOMO GENERAL HOSPITAL.
Dr.Saad Dakhil. Overview About Kidney Cancer According to the American Cancer Society, an estimated 58,240 people in the United States will be diagnosed.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Dr.Amit Gupta Associate Professor Dept. of Surgery
Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome  WILLIAM M.
Lymph Node Dissection for Renal Cell Carcinoma: When, How and Why?
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
Prognosis of younger patients in non-small cell lung cancer
MANAGEMENT OF SMALL RENAL TUMORS: Current Evidence
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Mahmood rasheed Hematology/oncology fellow VCU Massey cancer center
European Urology Oncology
SORVEGLIANZA ATTIVA DELLE PICCOLE MASSE RENALI
Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome  WILLIAM M.
Nat. Rev. Urol. doi: /nrurol
Presentation transcript:

Management of T1 Kidney Cancer Laparoscopic Surgery Karim Touijer, MD

Kidney Cancer is a Misnomer!!! Kidney cancer = is not a single disease Kidney cancer = Compendium of a number of different cancers that originate in the Kidney Each have a distinct: - Clinical course - Prognosis - Genetic background

Clear cell type or Conventional Most common (75%) +++ Aggressive ++ Accounts for most metastatic cases Mutation in VHL gene

Papillary Type 1 15% of kidney cancers Multifocal Bilateral Relatively low risk of Metastases Mutation of c-Met proto –oncogene on Chrs 7

Papillary Type 2 Aggressive +++ Metastatic potential Mutation of the Fumarate Hydratase gene

Chromophobe 5% of kidney cancers Less aggressive than conventional Could be associated to the Birt-Hogg-Dube

Oncocytoma Benign Metastases are rare

Management of T1 RCC - Ideal Scenario - Diagnosis Identify the histologic subtype Treatment Treat accordingly

Management of T1 RCC - Current Status - Diagnosis (-) Renal Tumor Imaging Needle Biopsy G250 scan Vascular density on US Treatment Renal Tumor Surgery Pathology (+++) Specific Histotype H&E Immunohistochemistry Genetic probes Tyrosine Kinase inhibitors for metastatic Clear Cell RCC

Surgical Treatment of T1 RCC Partial vs. radical Nephrectomy Laparoscopic vs. Open approach Investigative therapy

Partial vs. Radical Nephrectomy Whenever possible Partial Nephrectomy should be the preferred treatment. Comparable long-term cancer control Lesser risks of Chronic renal insufficiency and proteinuria

Partial vs Radical Nephrectomy ~ Cancer Control ~

Partial vs Radical Nephrectomy ~ Cancer Control ~

Chronic Kidney Disease

Chronic Kidney Disease

Results New Onset of GFR < 60 Median Time to GFR < 60 RN: 18 months PN: Was not reached Solid: Partial Nephrectomy Dashed: Radica1 Nephrectomy

Laparoscopic vs Open No Randomized Trial !? Cancer control Morbidity and Convalescence

Oncologic Outcomes for T1 and T2 Disease LAP 5 year cancer-specific survival for T1: 95% - 98% 5 year cancer-specific survival for T2: 92% Portis et al. J Urol. 167:1257, 2002 Ono et al. J Urol. 169: 77, 2003 Local recurrence rate up to 4.1% Open 5 year cancer-specific survival for T1: 90%-95% 5 year cancer-specific survival for T2: 74%-88% Tsui et al. J Urol. 163: 1090, 2000 Javidan et al. J urol. 162: 730, 1999 Local recurrence for T1 and T2 is ~ 4%. Lee et al. J Urol. 163: 730, 2000 Gogus et al. Urology 61: 926, 200

Morbidity of Partial Nephrectomy Lap vs. open Review of the recent MSKCC experience

Patient Characteristics Open Laparoscopic p-value n (%) 337 (90) 36 (10) Age, years, mean (SD) 61 (13) 60 (11) 0.537 Gender Males (%) 204 (60) 27 (75) Females (%) 133 (40) 9 (25) Laterality Left 168 (50) 21 58 0.383 Right 169 15 42 0.289 Incidentally Detected (%) 278 (82) 1.0 Size, cm, mean (SD) 3.0 (1.5) 2.4 (1.0) 0.05 Location (%) Peripheral 161 (48) 18 0.118 Central 128 (38) 17 (47) Missing 48 (14) 1 (3) ASA Score>2 (%) 122 (36) 11 (31) 0.584

Operative/Postop Data Open Laparoscopic p-value n (%) 337 (90) 36 (10) Clamp (%) 291 (89) 34 (94) 0.559 Clamp Time, min, mean (SD) 38 (18) 37 0.760 OR Time, min, mean (SD) 162 (49) 249* (83) <0.001 EBL, cc, mean (SD) 403 (378) 343 (398) 0.367 Conversion to Radical nephrectomy (%) 31/390 (8) 3/41 (7) 1.00 Positive Margins (%) 13 (4) 2 (5) 0.138 Length of Stay, days mean (SD) 4.8 (2.4) 3.1 (1.9) *Includes time for cystoscopy and stent placement

Complications Laparoscopic group Open group 10 complications in 8 patients 22% complication rate Open group 80 complications in 69 patients 20% complications rate

Complication MSKCC Grading System Grade I: Oral medication or bedrest Grade II: IV therapy or thoracostomy tube Grade III: Intubation, interventional radiology, endoscopy or reoperation Grade IV: Major organ resection or chronic disability Grade V: Death

Complications by Grade Open Laparoscopic 1 47 13.0% 5 13.9% 2 15 4.2% 2.8% 3 10 5.6% 4 0.6% 0.0%

Priorities in the management of T1 renal Conclusions Priorities in the management of T1 renal cell carcinoma are: Identifying the histotype at the time of Diagnosis +++ Using a partial nephrectomy as much as possible ++ Lap vs. Open: depending on the available skills